TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9413851
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (group H)
Study: 29040231
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion through an OnQ pump
Study: 27207739
Drug: Gel control
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel control
Study: 17640421
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice without vitamin C (L)
Study: 31621668
Drug: Dexmedetomidine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (Group D) 1 μg/kg
Study: 31621668
Drug: Esmolol (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (Group E) 2 mg/kg
Study: 31621668
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexmedetomidine and esmolol (Group DE) 0.5 μg/kg dexmedetomidine with 1 mg/kg esmolol
Study: 22691110
Drug: Inhaled atropine
Normalized name: atropine sulfate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled atropine sulfate via MicroDose Dry-Powder Inhaler (DPIA), 1.95 mg (5 doses × 0.4 mg per dose delivered over 12 min)
Study: 22691110
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) atropine via auto-injector (AUTO), 2 mg
Study: 18590586
Drug: Inulin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (10 g/d) for 16 days
Study: 11230611
Drug: oral trimethoprim/sulfamethoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral trimethoprim/sulfamethoxazole (TMP/SMX)
Study: 11230611
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1% PER and TMP/SMX
Study: 9149675
Drug: CO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO inhalation (1000 ppm for first 30 minutes, 100 ppm for last 30 minutes)
Study: 9149675
Drug: Vehicle (room
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (room air inhalation)
Study: 27756884
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (ACT) in stage II patients with high E2F score
Study: 27756884
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (ACT) in stage II patients with low E2F score
Study: 25539792
Drug: Pulmonary perfusion
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary perfusion with oxygenated blood or Custodiol™ HTK solution
Study: 25441486
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day soy isoflavone supplementation
Study: 25441486
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg calcium carbonate (Control)
Study: 20578658
Drug: Traditional buccal/palatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional buccal/palatal injections
Study: 14663900
Drug: Sorbilact infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbilact infusion (twice a day for 4 days postoperatively)
Study: 1387972
Drug: Hepaccine‐B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepaccine‐B vaccine (3 micrograms) at schedules of 0, 2, 6, 12 months
Study: 1387972
Drug: Hepaccine‐B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepaccine‐B vaccine (3 micrograms) at schedules of 0, 1, 6, 12 months
Study: 1387972
Drug: Hepaccine‐B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepaccine‐B vaccine (3 micrograms) at schedule of 0, 1, 2, 9 months
Study: 1387972
Drug: Hevac‐B Pasteur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hevac‐B Pasteur vaccine (5 micrograms) at schedule of 0, 1, 2, 9 months
Study: 3885084
Drug: Tripotassium dicitrato-bismuthate
Normalized name: tripotassium glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato-bismuthate tablet
Study: 24712563
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human GIP infusion with sitagliptin (inhibition of dipeptidyl peptidase 4)
Study: 24712563
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human GIP infusion with placebo
Study: 24712563
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human GLP‐1 infusion with sitagliptin (inhibition of dipeptidyl peptidase 4)
Study: 24712563
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human GLP‐1 infusion with placebo
Study: 15571444
Drug: Qualitative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative group earned incentives for providing urines with concentrations <300 ng/ml
Study: 11421506
Drug: Terbutaline Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline Turbuhaler 0.5 mg
Study: 7506239
Drug: 0.05% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% chlorhexidine gluconate solution irrigation
Study: 3030650
Drug: TFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFT plus one drop daily of rHu IFN-alpha 2 arg (30 million iu/ml)
Study: 3030650
Drug: TFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFT plus rHu IFN-gamma (30 million iu/ml)
Study: 3030650
Drug: TFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFT plus a mixture of alpha plus gamma (0.3 million iu/ml each)
Study: 3030650
Drug: TFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFT plus a mixture of alpha plus gamma (1.5 million iu/ml each)
Study: 3030650
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of alpha plus gamma at a moderate titer (1.5 million iu/ml each)
Study: 31819304
Drug: Oral probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotics (2x1 starting from the third postoperative day for 30 days, followed by 1x1 for two weeks each month for one year)
Study: 28956773
Drug: Metoprolol (100±53
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100±53 mg/d)
Study: 18522686
Drug: HMB supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB supplementation (300 mg HMB/kg feed)
Study: 2942630
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with codeine (650 mg plus 60 mg every 4 to 6 hours)
Study: 2942630
Drug: Diflunisal (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (1,000 mg initially then 500 mg twice a day)
Study: 31500602
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (TAU+)
Study: 31888765
Drug: Incentive spirometer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive spirometer therapy (IS)
Study: 31888765
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IS therapy)
Study: 24119064
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide gel with fluoride and potassium nitrate
Study: 24119064
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide gel without desensitizers
Study: 23062408
Drug: Xueshuantong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xueshuantong Injection (175 mg/d)
Study: 11489752
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of lycopene twice daily for 3 weeks
Study: 9703292
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg day(-1) for 12 months
Study: 31987958
Drug: Ultrahypofractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrahypofractionated radiation therapy
Study: 31987958
Drug: Increasing dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing dose per fraction in the experimental arm
Study: 31987958
Drug: Biochemical control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biochemical control at doses above approximately 80 Gy
Study: 20232750
Drug: Malaria vaccine
Normalized name: malaria vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria vaccine development
Study: 20232750
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of control measures (e.g., drugs, larvicides, clearing breeding sites)
Study: 3277608
Drug: Concurrent controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent controls
Study: 11314876
Drug: Daily left
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) for 2 weeks (total of 16,000 stimuli)
Study: 9771414
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution
Study: 30378768
Drug: Family-based behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioural weight loss treatment (FBT)
Study: 29205515
Drug: Yoga training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga training (three 1-hour sessions weekly for 1 year)
Study: 29205515
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intervention, monitored monthly)
Study: 22257997
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ethyl chloride spray)
Study: 22257997
Drug: Before skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before skin preparation
Study: 22257997
Drug: After skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: After skin preparation but before application of ethyl chloride
Study: 17651076
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day soyoligosaccharide intake (LSO)
Study: 17651076
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day soyoligosaccharide intake (HSO)
Study: 16324022
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered at a rate of 20 mg.30 s(‐1) (i.e. 40 mg.min(‐1)) until BIS value reached 35‐45; Group CP required lower dosage of propofol for induction (P = 0.03).
Study: 9435364
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution at a rate of 1000 ml/h
Study: 9435364
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution at a rate of 500 ml/h
Study: 8387966
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg twice daily for the first day, followed by 500 mg once daily for four days)
Study: 8387966
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily for 14 days)
Study: 3814200
Drug: Cyclosporine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (10 mg/kg/day)
Study: 3814200
Drug: Azathioprine (2.5‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5‐3 mg/kg/day)
Study: 31656130
Drug: Sucralose (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (8 × 5 g packets/day)
Study: 31656130
Drug: Steviol glycosides
Normalized name: Steviol Glycosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steviol glycosides (4 × 1 g packets/day)
Study: 31656130
Drug: Sucrose (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (8 × 5 g packets/day)
Study: 28746153
Drug: Intravenous Patient-Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Patient-Controlled Analgesia (IV-PCA)
Study: 25251249
Drug: Virtual reality-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-based rehabilitation combined with conventional occupational therapy (30 mins/session for 9 sessions)
Study: 25251249
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (30 mins/session for 15 sessions)
Study: 19228530
Drug: E75 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E75 peptide vaccine plus granulocyte-macrophage colony-stimulating factor
Study: 19228530
Drug: E75 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E75 peptide vaccine
Study: 19228530
Drug: E75 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E75 peptide vaccine (excluding 3 patients with PSA recurrences during vaccine series)
Study: 15232762
Drug: Elective preterm
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective preterm delivery with management plan including high-resolution ultrasound, weekly re-evaluation, corticosteroids, and delivery if bowel compromise present > 30 weeks
Study: 9433369
Drug: Fexofenadine 120
Normalized name: fexofenadine hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 120 mg once daily
Study: 10929922
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg once daily
Study: 8491949
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (local nasal immunotherapy with macronized powder extract)
Study: 3434850
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg) tablets
Study: 27863331
Drug: Inpatient enhanced
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient enhanced cognitive behavioural therapy for eating disorders (CBT-E)
Study: 26540083
Drug: Dalfampridine extended
Normalized name: Dalfampridine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine extended release (D-ER) 10 mg twice daily
Study: 21194006
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment to avascular retina (Group A)
Study: 21194006
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment to avascular retina and ridge (Group B)
Study: 21194006
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment to ridge (Group B)
Study: 19922017
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg prednisolone daily
Study: 25109606
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg daily + intensive lifestyle modification (LSM)
Study: 11996957
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg daily
Study: 21715141
Drug: Intensive bimanual
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive bimanual training (Hand‐Arm Bimanual Intensive Therapy: HABIT)
Study: 21715141
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Constraint‐Induced Movement Therapy, CIMT)
Study: 10749820
Drug: Carbohydrate loading
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate loading (9 g CHO/kg body mass/day)
Study: 10749820
Drug: Placebo-controlled moderate-CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-controlled moderate-CHO diet (6 g CHO/kg body mass/day)
Study: 9051168
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (3 sessions, one weekly for 3 weeks, stimulating Bladder 10 and Gall Bladder 20 points)
Study: 9051168
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (17 patients treated with drugs - FANS and myorelaxing - and physiotherapy)
Study: 1627436
Drug: Single cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cycle of combination chemotherapy (intravenous cyclophosphamide, methotrexate, and fluorouracil)
Study: 1627436
Drug: Single cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cycle of combination chemotherapy
Study: 1627436
Drug: Single cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cycle of combination chemotherapy (in postmenopausal women with ER-negative tumors)
Study: 1627436
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment (in postmenopausal women with ER-negative tumors)
Study: 6392047
Drug: Nicergoline (Sermion)
Normalized name: nicergoline
DrugBank: Nicergoline (DB00699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (Sermion) treatment for one year
Study: 30782199
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + SI (sustained inflation)
Study: 17805132
Drug: Corticotomy‐assisted orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotomy‐assisted orthodontic treatment
Study: 15105223
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg preincisional and 0.2 mg/kg intraoperative S(+)‐ketamine repeated at 20‐min intervals
Study: 11378011
Drug: Talinolol (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol (titrated up to 100 mg/day starting with 12.5 mg daily)
Study: 11378011
Drug: Talinolol (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol (titrated up to 150 mg/day starting with 12.5 mg daily)
Study: 9358933
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (specifics not provided)
Study: 9839638
Drug: Observation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation of individual tumour response to primary medical treatment
Study: 9110909
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg a day)
Study: 9110909
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (selegiline and alpha-tocopherol)
Study: 1911319
Drug: Oral terbinafine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine, 250 mg, once daily for 2 weeks
Study: 1911319
Drug: Placebo, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily for 2 weeks
Study: 30280635
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (200 mg of pembrolizumab, carboplatin, and either paclitaxel or nab-paclitaxel)
Study: 30280635
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo plus chemotherapy (saline placebo, carboplatin, and either paclitaxel or nab-paclitaxel)
Study: 30280635
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo plus chemotherapy
Study: 7816407
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil supplements
Study: 2836259
Drug: heparin-dihydergot (HDHE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin-dihydergot (HDHE) (2 X 5000 IU heparin with 0.5 mg DHE from Days 1 to 8)
Study: 2836259
Drug: heparin-dihydergot (HDHE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin-dihydergot (HDHE)
Study: 24935282
Drug: FAc 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAc 0.2 μg/day
Study: 20362397
Drug: Diazepam (benzodiazepine)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (benzodiazepine) in addition to mechanical physiotherapy and analgesics for 7 days
Study: 20362397
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to mechanical physiotherapy and analgesics for 7 days
Study: 18456901
Drug: Therapist-assisted self-administered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-assisted self-administered parent training (SDPT+T)
Study: 14601352
Drug: Venlafaxine XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine XL (75 mg, with potential dose doubling after 2 weeks)
Study: 10424326
Drug: Acuvue contact
Normalized name: ketotifen Drug-Eluting Contact Lens [Acuvue Theravision]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acuvue contact lenses soaked in 0.3% eye drop solutions
Study: 8739655
Drug: Aredia (pamidronate)
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aredia (pamidronate) 90 mg i.v. every 4 weeks
Study: 1736944
Drug: NdYAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: NdYAG laser treatment
Study: 6496560
Drug: Hydrochlorothiazide tablets
Normalized name: Hydrochlorothiazide Tablets
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide tablets
Study: 6496560
Drug: Maxzide tablets
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maxzide tablets
Study: 6496560
Drug: Dyazide capsules
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dyazide capsules
Study: 16996808
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of home blood pressure monitoring and tailored behavioral intervention
Study: 15623574
Drug: High mannan
Normalized name: Konjac mannan
DrugBank: Konjac mannan (DB14963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High mannan binding lectin (MBL) levels (>1,000 microg/L) in the cross-sectional group (n = 987)
Study: 9036717
Drug: Parenteral gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral gold
Study: 7794044
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide (THA) 20 mg in 1 ml
Study: 7794044
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% normal saline, 1 ml)